

# Jakub Závada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7086381/publications.pdf>

Version: 2024-02-01

65  
papers

2,798  
citations

331670

21  
h-index

175258

52  
g-index

69  
all docs

69  
docs citations

69  
times ranked

3935  
citing authors

#	ARTICLE	IF	CITATIONS
1	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	3.0	3
2	European bio-naĀve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	1.9	7
3	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	2.0	7
4	Switching first-line targeted therapy after not reaching low disease activity within 6Āmonths is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 11.	3.5	5
5	OUP accepted manuscript. <i>Rheumatology</i> , 2021, , .	1.9	0
6	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1410-1418.	0.9	28
7	Patients with REM sleep behavior disorder have higher serum levels of allantoin. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 38-43.	2.2	2
8	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38.	0.9	225
9	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 183-192.	3.1	5
10	Rapid and reliable HILIC-MS/MS method for monitoring allantoin as a biomarker of oxidative stress. <i>Analytical Biochemistry</i> , 2020, 589, 113509.	2.4	13
11	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	3.8	33
12	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 97.	3.5	22
13	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , 2020, 47, 658-667.	2.0	7
14	Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3Āmonths of treatment with TNF inhibitors. <i>Rheumatology International</i> , 2019, 39, 1749-1757.	3.0	14
15	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	2.8	8
16	AB0872Ā...OXIDATIVE STRESS MARKER ALLANTOIN IS NOT ASSOCIATED WITH THE CHANGE OF SERUM URIC ACID LEVEL IN PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES AFTER ABROGATION OF SYSTEMIC INFLAMMATION BY TNF INHIBITION. , 2019, , .		0
17	FR10107Ā...THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
18	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , 2019, 39, 469-478.	3.0	23

#	ARTICLE	IF	CITATIONS
19	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 342-343.	0.8	8
20	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 338-339.	0.8	1
21	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , 2018, 37, 2055-2062.	2.2	23
22	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47
23	The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies. <i>JMIR Research Protocols</i> , 2018, 7, e165.	1.0	16
24	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.6	19
25	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.9	150
26	2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42.	0.9	1,096
27	Functional non-synonymous variants of ABCG2 and gout risk. <i>Rheumatology</i> , 2017, 56, 1982-1992.	1.9	62
28	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.9	77
29	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	3.0	9
30	05.04â€¦Functional polymorphisms of the abcg2 gene in primary gout. , 2017, , .		0
31	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis â€œ a cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 5.	3.5	15
32	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. <i>PLoS ONE</i> , 2017, 12, e0183420.	2.5	32
33	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1â€¦year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 96-102.	0.9	61
34	AB0952â€¦Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1227.1-1227.	0.9	0
35	A6.18â€¦Analysis of <i>ABCG2</i> gene in primary hyperuricemia and gout. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A55.1-A55.	0.9	0
36	EQ-5D in Central and Eastern Europe: 2000â€œ2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	3.1	103

#	ARTICLE	IF	CITATIONS
37	FRI0544â€¦Impact of Education in Musculoskeletal Ultrasonography: Good To Excellent Reliability Results in Modified US7 Scoring System after One Year of Continuing Education since Basic or Intermediate Level of Training. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 637.1-637.	0.9	0
38	FRI0532â€¦Association between The 7-Joint Ultrasound Score (US7S) and Physical Function in Rheumatoid Arthritis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 632.1-632.	0.9	0
39	Novel dysfunctional variant in <i>ABCG2</i> as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. <i>Rheumatology</i> , 2016, 55, 191-194.	1.9	24
40	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , 2016, 11, e0165498.	2.5	14
41	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 341.	3.5	14
42	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	1.9	22
43	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. <i>Arthritis Research and Therapy</i> , 2015, 17, 371.	3.5	20
44	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 252.	3.5	60
45	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , 2015, 20, 47-51.	1.9	12
46	A2.5â€¦Novel dysfunctional variant in <i>ABCG2</i> gene is a cause of primary hyperuricemia and gout: biochemical, molecular genetic and functional analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A17.2-A17.	0.9	0
47	THU0168â€¦Monotherapy with Biological Disease-Modifying Anti-Rheumatic Drugs-Data from the Czech Registry Attra.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 238.2-238.	0.9	0
48	SAT0349â€¦A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 719.1-719.	0.9	1
49	SAT0532â€¦Updated Eular Evidence-Based Recommendations for the Diagnosis of Gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 783.3-784.	0.9	7
50	SAT0531â€¦Updated Eular Evidence-Based Recommendations for the Management of Gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 783.2-783.	0.9	2
51	SAT0205â€¦Potential of US 7 Score in Evaluating of Disease Activity of Patients with Rheumatoid Arthritis in the State of Remission. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 664.1-664.	0.9	0
52	Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. <i>Lupus</i> , 2014, 23, 69-74.	1.6	28
53	Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 628-628.	0.9	18
54	The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 252-255.	0.9	21

#	ARTICLE	IF	CITATIONS
55	SAT0188â€¦Serum Calprotectin (S100A8/9) Correlates with Clinical and Ultrasound Outcomes in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 658.1-658.	0.9	0
56	Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. <i>Rheumatology International</i> , 2013, 33, 259-263.	3.0	36
57	A10.3â€¦Arthritis in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A72.2-A72.	0.9	1
58	Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A15.2-A15.	0.9	0
59	&lt;i>Mycobacterium marinum&/i>; Epididymoorchitis: Case Report and Literature Review. <i>Urologia Internationalis</i> , 2011, 87, 120-124.	1.3	10
60	Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. <i>Lupus</i> , 2010, 19, 1281-1289.	1.6	111
61	A comparison of three methods to estimate baseline creatinine for RIFLE classification. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3911-3918.	0.7	206
62	Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology</i> , 2009, 48, 1197-1201.	1.9	18
63	Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up. <i>Archives of Medical Research</i> , 2009, 40, 276-284.	3.3	25
64	Circulating Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 247-254.	2.0	21
65	Two familial cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <i>Rheumatology</i> , 2006, 45, 356-357.	1.9	6